CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for
developmental disorders and cancer diagnostics, announced today
that it has entered into an agreement to issue securities in a
registered direct offering to accredited institutional pre-existing
investors that will result in gross proceeds to the Company
totaling $4.9 million.
The Company entered into a definitive purchase agreement with
such investors pursuant to which the Company has agreed to sell up
to 1,542,000 shares of common stock at a negotiated price of $1.75
per share and up to 2,201.50 units consisting of Series E
convertible preferred stock and warrants. Each unit consists
of one share of Series E convertible preferred stock and a warrant
to purchase approximately 317.965 shares of common stock, at an
exercise price of $1.97 per share. Each unit will be sold at a
negotiated price of $1,000. In total, the Series E preferred is
convertible into up to 1,258,000 shares of common stock and the
warrants are exercisable for up to 700,000 shares of common
stock.
The warrants are not exercisable for six months following their
issue date and will expire on the fifth anniversary of the date the
warrants become exercisable. The Series E preferred
stock is convertible at $1.75 per share (subject to price
anti-dilution protection) and accrues an annual dividend of 6
percent beginning six months after closing. The closing of the
offering is expected to take place on or prior to February 20,
2015, subject to the satisfaction of customary closing
conditions. The estimated net proceeds to the Company from the
offering, after deducting estimated offering expenses payable by
us, are expected to be approximately $4.75 million, to be used for
general corporate purposes.
A shelf registration statement (File No. 333-198848) relating to
the shares of common stock, preferred stock and warrants issued in
the registered direct offering (and the shares of common stock
issuable upon conversion of the preferred stock and exercise of the
warrants) has been filed with and declared effective by the
Securities and Exchange Commission (the "SEC"). A prospectus
supplement relating to the registered direct offering will be filed
by the Company with the SEC. Copies of the prospectus
supplement, together with the accompanying prospectus, can be
obtained at the SEC's website at http://www.sec.gov or from
CombiMatrix Corporation, 300 Goddard, Suite 100, Irvine California
92618, Attention: Investor Relations.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of the Company in
the registered direct offering. There shall not be any offer,
solicitation of an offer to buy, or sale of securities in any state
or jurisdiction in which such an offering, solicitation, or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Any
registered direct offering will be made only by means of a
prospectus, including a prospectus supplement, forming a part of
the effective registration statement.
Substantially concurrently with the registered direct offering,
the Company entered into a separate definitive purchase agreement
in a private placement with accredited institutional pre-existing
investors pursuant to which the Company has agreed to sell warrants
to purchase up to 1,540,000 shares of common stock. The
private placement warrants will be sold for an aggregate negotiated
purchase price of $1,000. The closing of the private placement
is expected to take place on or prior to February 20, 2015, subject
to the satisfaction of customary closing conditions. The
private placement warrants will not be issued unless and until the
Company's stockholders approve amending the Company's Certificate
of Incorporation to increase the Company's authorized common stock
in an amount sufficient to permit the issuance of the common stock
issuable upon exercise of the private placement warrants.
When issued, the private placement warrants will have an
exercise price of $2.167 per share, will not be exercisable for six
months following the date of the private placement purchase
agreement and will expire on the fifth anniversary of the date such
warrants become exercisable. In connection with the purchase
of the private placement warrants, the Company has agreed to modify
previously issued and outstanding warrants held by the private
placement investors that were issued on October 1, 2012, March 20,
2013, May 6, 2013 and June 28, 2013, to (i) reduce the exercise
prices thereunder to $1.97 and (ii) prohibit the exercise of such
modified warrants for a period of six months after the date of the
modification.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described above, nor
shall there be any sale of such securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction. The private placement warrants have not
been registered under the Securities Act of 1933, as amended, or
any state securities laws, and may not be offered or sold in the
United States absent registration with the Securities and Exchange
Commission or an applicable exemption from such registration
requirements.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not
limited to, the amount and use of proceeds we expect to receive
from the offerings, the closing of the offerings, and the
conversion of the preferred stock and the exercise of the warrants.
Such forward-looking statements are inherently subject to certain
risks, trends and uncertainties, many of which we cannot predict
with accuracy and some of which we might not even anticipate, and
involve factors that may cause actual results to differ materially
and adversely from those projected or suggested. Readers are
cautioned not to place undue reliance on these forward-looking
statements and are advised to consider the factors listed above
together with the additional factors under the heading
"Forward-Looking Statements" and "Risk Factors" in our Annual
Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other
filings with the Securities and Exchange Commission. We
undertake no obligation to revise or update publicly any
forward-looking statements for any reason, except as required by
law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Investor Contact:
Robert Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Media Contact:
David Schull or Lena Evans
Russo Partners LLC
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com
robert.flamm@russopartnersllc.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Apr 2023 to Apr 2024